Recruiting PHASE2 INTERVENTIONAL 2-arm NCT06045260

Receptor Radionuclide Therapy With 177Lu-DOTATOC (LUFOR)

Receptor Radionuclide Therapy With 177Lu-DOTATOC (177Lu-edotreotide or 177Lu-octreotide) in SSTR Positive Patients: a Multicenter, Prospective, Phase II Trial

Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Conditions Neuroendocrine Tumors Paraganglioma Pheochromocytoma

Interventions 177Lu-DOTATOC

Updated 4 times since 2023 Last updated: Aug 9, 2024 Started: Sep 13, 2023 Primary completion: Feb 28, 2025 Completion: Jan 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06045260, this PHASE2 trial focuses on Neuroendocrine Tumors and Paraganglioma and remains actively recruiting participants. Sponsored by Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS, it has been updated 4 times since 2023, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Apr 2025 — Present [monthly]

Recruiting PHASE2
Sep 2024 — Apr 2025 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2
Oct 2023 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Sep 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Data source: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cesena, Italy
• Meldola, Italy